Related Experiment Video
Updated: Apr 19, 2026

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
Published on: August 1, 2025
Endocannabinoid signalling and the deteriorating brain
Vincenzo Di Marzo1, Nephi Stella2, Andreas Zimmer3
1Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy.
Abstract:
Ageing is characterized by the progressive impairment of physiological functions and increased risk of developing debilitating disorders, including chronic inflammation and neurodegenerative diseases. These disorders have common molecular mechanisms that can be targeted therapeutically. In the wake of the approval of the first cannabinoid-based drug for the symptomatic treatment of multiple sclerosis, we examine how endocannabinoid (eCB) signalling controls--and is affected by--normal ageing and neuroinflammatory and neurodegenerative disorders. We propose a conceptual framework linking eCB signalling to the control of the cellular and molecular hallmarks of these processes, and categorize the key components of endocannabinoid signalling that may serve as targets for novel therapeutics.
Insights
The endocannabinoid system impacts ageing and neurodegenerative diseases. Targeting this system offers potential therapeutic strategies for age-related conditions and inflammation.
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- Ageing leads to physiological decline and increased risk of neurodegenerative diseases and chronic inflammation.
- These age-related disorders share common molecular pathways.
- Cannabinoid-based drugs are emerging as therapeutic options, notably for multiple sclerosis.
Purpose of the Study:
- To investigate the role of endocannabinoid (eCB) signaling in normal aging.
- To understand how eCB signaling is altered in neuroinflammatory and neurodegenerative disorders.
- To identify potential therapeutic targets within the eCB system.
Main Methods:
- Review of existing literature on eCB signaling, aging, and neurodegeneration.
- Conceptual framework development linking eCB signaling to aging hallmarks.
- Analysis of eCB system components for therapeutic potential.
Main Results:
- eCB signaling plays a crucial role in regulating processes associated with normal aging.
- Dysregulation of eCB signaling is implicated in neuroinflammation and neurodegeneration.
- Specific components of the eCB system present viable therapeutic targets.
Conclusions:
- The endocannabinoid system is a key modulator of aging and age-related neurological conditions.
- Targeting the eCB system offers a promising avenue for developing novel therapeutics.
- Further research into eCB signaling mechanisms can advance treatments for debilitating age-related diseases.
Related Concept Videos
Gut-Brain Axis
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Alzheimer Disease ll: Pathophysiology
Hepatic Encephalopathy
Long-term Depression
Calcium Ion Concentration Mechanism
If over...

